Sichuan Kelun Pharmaceutical Co., Ltd.
Founded in 1996, Kelun has now formed a "Pin"-shaped architecture operation platform composed of Kelun Pharmaceutical, Chuanning Biotechnology and Kelun Botai, with a total market value of over 100 billion yuan. In 2018, Kelun was named "Manufacturing Single Champion Demonstration Enterprise" for his global advantages in large-capacity injections. Sichuan Kelun Pharmaceutical Co., Ltd. was successfully listed on the Shenzhen Stock Exchange in June 2010, and immediately launched the 10 billion industry investment plan and began to implement the development strategy of "three-in-one developments, innovative growth". The first engine maintains Kelun's leading position in the infusion field through continuous industrial upgrading and variety structure adjustment; the second engine builds from intermediates, raw materials to preparations through innovative development and utilization of high-quality natural resources. The third engine accumulates the ultimate driving force for the everlasting enterprise foundation through the construction of the R&D system and diversified technological innovation. In the field of infusion, Kelun has achieved comprehensive industrial upgrading, and has the profitability of both high-end manufacturing and new materials, occupying a strategic high ground for technological innovation and quality benchmarks. Columbia has established a closed responsibility system from drug research and development, production and manufacturing, logistics and transportation to terminal use to ensure product quality and safety. The leading products have been exported in batches and enjoy a high reputation in more than 50 countries and regions. The stand-up bag® independently developed by Kelun is the first at home and abroad. It has more than 20 patents and has won the National Science and Technology Progress Award. It has higher safety and cost-effectiveness than traditional infusions, and has great application value in reducing energy consumption and environmental protection, representing the direction of development of Chinese infusion products. In the field of antibiotics, the company has established Yili Chuanning Biotechnology Co., Ltd. to produce erythromycin thiocyanate and cephalosporin series intermediates. Through R&D testing, upgrading and optimization, innovative cooperation, and the introduction of advanced domestic and foreign technology equipment, Sichuan Ning has been approved to build a National Environmental Protection Antibiotic Bacterial Slag Harmless Treatment and Resource Utilization Engineering Technology Center, solving the source problems of the antibiotic industry. In December 2022, Chuanning Biotech was successfully listed on the Shenzhen Stock Exchange GEM and entered the field of synthetic biology. Kelun has applied for more than 1,300 invention patents and obtained more than 700 invention patents. He has launched the development of more than 500 major drugs in many diseases such as tumors, bacterial infections, parenteral nutrition, etc.; since 2017, it has been approved for marketing every year. More than 20 items have become the leading generic drug enterprise in China, and has become the leading supplier of national centralized drug procurement with a winning rate of nearly 90%. At the same time, more than ten innovations are used to treat major diseases such as tumors, autoimmunity, inflammation, and metabolism. The drug project is in its clinical stage, with multiple clinical trials being a global multi-center research. Multiple projects work together with European and American partners to deploy global clinical research and are carried out simultaneously in multiple countries including China and Europe and the United States to achieve the synergy of pipelines and technology platforms. Effects, maximize the global value of pipelines.
Sichuan Kelun Pharmaceutical Co., Ltd.
Founded in 1996, Kelun has now formed a "Pin"-shaped architecture operation platform composed of Kelun Pharmaceutical, Chuanning Biotechnology and Kelun Botai, with a total market value of over 100 billion yuan. In 2018, Kelun was named "Manufacturing Single Champion Demonstration Enterprise" for his global advantages in large-capacity injections. Sichuan Kelun Pharmaceutical Co., Ltd. was successfully listed on the Shenzhen Stock Exchange in June 2010, and immediately launched the 10 billion industry investment plan and began to implement the development strategy of "three-in-one developments, innovative growth". The first engine maintains Kelun's leading position in the infusion field through continuous industrial upgrading and variety structure adjustment; the second engine builds from intermediates, raw materials to preparations through innovative development and utilization of high-quality natural resources. The third engine accumulates the ultimate driving force for the everlasting enterprise foundation through the construction of the R&D system and diversified technological innovation. In the field of infusion, Kelun has achieved comprehensive industrial upgrading, and has the profitability of both high-end manufacturing and new materials, occupying a strategic high ground for technological innovation and quality benchmarks. Columbia has established a closed responsibility system from drug research and development, production and manufacturing, logistics and transportation to terminal use to ensure product quality and safety. The leading products have been exported in batches and enjoy a high reputation in more than 50 countries and regions. The stand-up bag® independently developed by Kelun is the first at home and abroad. It has more than 20 patents and has won the National Science and Technology Progress Award. It has higher safety and cost-effectiveness than traditional infusions, and has great application value in reducing energy consumption and environmental protection, representing the direction of development of Chinese infusion products. In the field of antibiotics, the company has established Yili Chuanning Biotechnology Co., Ltd. to produce erythromycin thiocyanate and cephalosporin series intermediates. Through R&D testing, upgrading and optimization, innovative cooperation, and the introduction of advanced domestic and foreign technology equipment, Sichuan Ning has been approved to build a National Environmental Protection Antibiotic Bacterial Slag Harmless Treatment and Resource Utilization Engineering Technology Center, solving the source problems of the antibiotic industry. In December 2022, Chuanning Biotech was successfully listed on the Shenzhen Stock Exchange GEM and entered the field of synthetic biology. Kelun has applied for more than 1,300 invention patents and obtained more than 700 invention patents. He has launched the development of more than 500 major drugs in many diseases such as tumors, bacterial infections, parenteral nutrition, etc.; since 2017, it has been approved for marketing every year. More than 20 items have become the leading generic drug enterprise in China, and has become the leading supplier of national centralized drug procurement with a winning rate of nearly 90%. At the same time, more than ten innovations are used to treat major diseases such as tumors, autoimmunity, inflammation, and metabolism. The drug project is in its clinical stage, with multiple clinical trials being a global multi-center research. Multiple projects work together with European and American partners to deploy global clinical research and are carried out simultaneously in multiple countries including China and Europe and the United States to achieve the synergy of pipelines and technology platforms. Effects, maximize the global value of pipelines.
China Resources Pharmaceutical Holdings Co., Ltd.
China Resources Shuanghe Pharmaceutical Co., Ltd. has a glorious history of more than 80 years. It was founded in 1939. It was originally a military pharmaceutical factory in the Taihang Mountain Revolutionary Base and was named the Minglihua Pharmaceutical Factory. In 1949, it moved to Beijing with the army and later renamed Beijing Pharmaceutical Factory. Developed into a large state-owned chemical pharmaceutical comprehensive preparation enterprise, laying the foundation of Beijing's modern chemical pharmaceutical industry; listed on the Shanghai Stock Exchange in 1997, renamed Beijing Shuanghe Pharmaceutical Co., Ltd., and became a cross-regional group based in Beijing and radiating across the country through external expansion; in 2010 It has entered the world's top 500 company under China Resources Group. It was renamed China Resources Double Crane in 2012 and is now one of the business units of China Resources Group's big health field. The company's main business covers new drug research and development, preparation production, drug sales, raw material production and pharmaceutical equipment, etc. It has rich product line and brand advantages, high-quality product quality and cost control, strong channel and terminal coverage and management capabilities, With international advantages, dynamic team advantages and profound cultural heritage, economic strength, competitive vitality and sustainable development capabilities rank among the forefront of domestic pharmaceutical companies. In 2022, the company achieved operating income of 9.447 billion yuan and net profit of 1.215 billion yuan. The company actively deploys four major business platforms: general drug business, infusion business, differentiated drug business and innovative drug business, and deeply cultivates chronic diseases, infusion, pediatrics, nephrology, mental/nervity and other fields, and enters the oncology field, No. 0, Fusui The annual sales of 18 key products, including Yue, nifedipine sustained-release tablets, Pivastatin calcium tablets, Tangshiping, BFS infusion, Kelisu, peritoneal dialysate, magnesium valproate sustained-release tablets, exceeded 100 million yuan. It owns trademarks such as "Shuanghe Tu", "Saike" and "Xiangzhong" and has won many honors. The company accelerates innovation and transformation, builds multiple technology platforms, continuously enriches product clusters, continues to increase R&D investment, actively cooperates with domestic and foreign universities, R&D institutions and pharmaceutical companies to accelerate product acquisition; has first-class domestic production and manufacturing capabilities, 20 companies The production bases are distributed in 14 provinces and cities in the country, including North China, Northwest China, Central China, South China and other regions, and have built an advanced production management system and quality management benchmarks against international first-class standards. The sales network covers 33 provinces, municipalities, autonomous regions and special administrative regions across the country. It has a strong influence in the North China, Jiangsu and Zhejiang and infusion base markets. Some raw materials and preparation products are exported to more than 40 countries in the international market. Through rich product support, thoughtful marketing services, good terminal control capabilities and professionalism The marketing team works together with customers for win-win results. In the future, China Resources Double Crane will continue to accelerate innovation transformation and quality development, implement China Resources Group's "1246" model, serve the people's livelihood of a great country, build a major weapon, and strive to become a world-class pharmaceutical company trusted by the public and driven by innovation, for the development of the industry and the public. Make greater contributions to health.
China Resources Pharmaceutical Holdings Co., Ltd.
China Resources Shuanghe Pharmaceutical Co., Ltd. has a glorious history of more than 80 years. It was founded in 1939. It was originally a military pharmaceutical factory in the Taihang Mountain Revolutionary Base and was named the Minglihua Pharmaceutical Factory. In 1949, it moved to Beijing with the army and later renamed Beijing Pharmaceutical Factory. Developed into a large state-owned chemical pharmaceutical comprehensive preparation enterprise, laying the foundation of Beijing's modern chemical pharmaceutical industry; listed on the Shanghai Stock Exchange in 1997, renamed Beijing Shuanghe Pharmaceutical Co., Ltd., and became a cross-regional group based in Beijing and radiating across the country through external expansion; in 2010 It has entered the world's top 500 company under China Resources Group. It was renamed China Resources Double Crane in 2012 and is now one of the business units of China Resources Group's big health field. The company's main business covers new drug research and development, preparation production, drug sales, raw material production and pharmaceutical equipment, etc. It has rich product line and brand advantages, high-quality product quality and cost control, strong channel and terminal coverage and management capabilities, With international advantages, dynamic team advantages and profound cultural heritage, economic strength, competitive vitality and sustainable development capabilities rank among the forefront of domestic pharmaceutical companies. In 2022, the company achieved operating income of 9.447 billion yuan and net profit of 1.215 billion yuan. The company actively deploys four major business platforms: general drug business, infusion business, differentiated drug business and innovative drug business, and deeply cultivates chronic diseases, infusion, pediatrics, nephrology, mental/nervity and other fields, and enters the oncology field, No. 0, Fusui The annual sales of 18 key products, including Yue, nifedipine sustained-release tablets, Pivastatin calcium tablets, Tangshiping, BFS infusion, Kelisu, peritoneal dialysate, magnesium valproate sustained-release tablets, exceeded 100 million yuan. It owns trademarks such as "Shuanghe Tu", "Saike" and "Xiangzhong" and has won many honors. The company accelerates innovation and transformation, builds multiple technology platforms, continuously enriches product clusters, continues to increase R&D investment, actively cooperates with domestic and foreign universities, R&D institutions and pharmaceutical companies to accelerate product acquisition; has first-class domestic production and manufacturing capabilities, 20 companies The production bases are distributed in 14 provinces and cities in the country, including North China, Northwest China, Central China, South China and other regions, and have built an advanced production management system and quality management benchmarks against international first-class standards. The sales network covers 33 provinces, municipalities, autonomous regions and special administrative regions across the country. It has a strong influence in the North China, Jiangsu and Zhejiang and infusion base markets. Some raw materials and preparation products are exported to more than 40 countries in the international market. Through rich product support, thoughtful marketing services, good terminal control capabilities and professionalism The marketing team works together with customers for win-win results. In the future, China Resources Double Crane will continue to accelerate innovation transformation and quality development, implement China Resources Group's "1246" model, serve the people's livelihood of a great country, build a major weapon, and strive to become a world-class pharmaceutical company trusted by the public and driven by innovation, for the development of the industry and the public. Make greater contributions to health.
China Otsuka Pharmaceutical Co., Ltd.
China Otsuka Pharmaceutical Co., Ltd. was jointly established by China Pharmaceutical Investment Co., Ltd. and Japan Otsuka Pharmaceutical Co., Ltd. It was approved and established in April 1981 and officially put into production on May 17, 1984. At the end of 2009, Tianjin Municipal Pharmaceutical Group Co., Ltd. has become one of the Chinese shareholders. China and Japan each hold 50% of the shares. The company has now become a comprehensive pharmaceutical manufacturer with COP brand large infusion, ampoule injection, eye drops and nutrition infusion products. It has established 29 branches across the country, covering 31 provinces, cities and regions across the country, forming It has a sales network throughout the country; and it already has two holding subsidiaries, including Guangdong Otsuka Pharmaceutical Co., Ltd. and Dalian Otsuka Pharmaceutical Co., Ltd. The company's headquarters is located in Xiqing District, Tianjin, with a factory covering an area of more than 100,000 square meters. The company has multiple advanced technology production lines, which can produce 4 major categories and 46 varieties of soft bag infusion, plastic bottle infusion and plastic ampoule injection products, as well as multiple eye drops and nutrition infusion products. Over the past 30 years, the products have been put on the market, and the quality of clinical infusion products has been stable with advanced technology and strict management. The products have been rated as national and local high-quality products many times and are welcomed by medical workers and patients.
China Otsuka Pharmaceutical Co., Ltd.
China Otsuka Pharmaceutical Co., Ltd. was jointly established by China Pharmaceutical Investment Co., Ltd. and Japan Otsuka Pharmaceutical Co., Ltd. It was approved and established in April 1981 and officially put into production on May 17, 1984. At the end of 2009, Tianjin Municipal Pharmaceutical Group Co., Ltd. has become one of the Chinese shareholders. China and Japan each hold 50% of the shares. The company has now become a comprehensive pharmaceutical manufacturer with COP brand large infusion, ampoule injection, eye drops and nutrition infusion products. It has established 29 branches across the country, covering 31 provinces, cities and regions across the country, forming It has a sales network throughout the country; and it already has two holding subsidiaries, including Guangdong Otsuka Pharmaceutical Co., Ltd. and Dalian Otsuka Pharmaceutical Co., Ltd. The company's headquarters is located in Xiqing District, Tianjin, with a factory covering an area of more than 100,000 square meters. The company has multiple advanced technology production lines, which can produce 4 major categories and 46 varieties of soft bag infusion, plastic bottle infusion and plastic ampoule injection products, as well as multiple eye drops and nutrition infusion products. Over the past 30 years, the products have been put on the market, and the quality of clinical infusion products has been stable with advanced technology and strict management. The products have been rated as national and local high-quality products many times and are welcomed by medical workers and patients.
Chenxin Pharmaceutical Co., Ltd.
Chenxin Pharmaceutical Co., Ltd. is currently a listed enterprise on the main board of the Shanghai Stock Exchange (stock abbreviation: Chenxin Pharmaceutical, stock code: 603367). It is a comprehensive pharmaceutical enterprise integrating R&D, production and sales, located in Jining City, Shandong Province. The company was established in 1970. Its predecessor was Jining No. 3 Pharmaceutical Factory. It was renamed Shandong Lu Kang Chenxin Pharmaceutical Co., Ltd. in 1998 and was renamed Chenxin Pharmaceutical Co., Ltd. in 2011. Chenxin Pharmaceutical takes it as its mission to ensure and improve the quality of life and health of patients. It uses 6% of its sales revenue every year to invest in scientific and technological research and development, and is committed to independently developing and producing pure innovative drugs; it has successively worked with China Pharmaceutical University and Shanghai Drug Research Institute of the Chinese Academy of Sciences. Research institutes such as the Institute, Academy of Military Medical Sciences, Shenyang Pharmaceutical University, Shandong University, Shandong Medical Academy, Shandong Medical Industry Research Institute have established stable cooperative relationships and successfully developed a "joint innovation of industry, education and research" The way. In the future, Chenxin Pharmaceutical will use the wings of the capital market to accelerate technological innovation and improve product quality. With excellent product quality and comprehensive and efficient supporting services, it will create value for customers, shareholders, employees and the society to achieve better results. The operating performance will be rewarded to all investors!
Chenxin Pharmaceutical Co., Ltd.
Chenxin Pharmaceutical Co., Ltd. is currently a listed enterprise on the main board of the Shanghai Stock Exchange (stock abbreviation: Chenxin Pharmaceutical, stock code: 603367). It is a comprehensive pharmaceutical enterprise integrating R&D, production and sales, located in Jining City, Shandong Province. The company was established in 1970. Its predecessor was Jining No. 3 Pharmaceutical Factory. It was renamed Shandong Lu Kang Chenxin Pharmaceutical Co., Ltd. in 1998 and was renamed Chenxin Pharmaceutical Co., Ltd. in 2011. Chenxin Pharmaceutical takes it as its mission to ensure and improve the quality of life and health of patients. It uses 6% of its sales revenue every year to invest in scientific and technological research and development, and is committed to independently developing and producing pure innovative drugs; it has successively worked with China Pharmaceutical University and Shanghai Drug Research Institute of the Chinese Academy of Sciences. Research institutes such as the Institute, Academy of Military Medical Sciences, Shenyang Pharmaceutical University, Shandong University, Shandong Medical Academy, Shandong Medical Industry Research Institute have established stable cooperative relationships and successfully developed a "joint innovation of industry, education and research" The way. In the future, Chenxin Pharmaceutical will use the wings of the capital market to accelerate technological innovation and improve product quality. With excellent product quality and comprehensive and efficient supporting services, it will create value for customers, shareholders, employees and the society to achieve better results. The operating performance will be rewarded to all investors!
Jimin Healthcare Management Co., Ltd.
Jimin Health Management Co., Ltd. (hereinafter referred to as the "Company") is a modern pharmaceutical enterprise founded in 1996. It is a key backbone enterprise in the pharmaceutical industry in Zhejiang Province and a national high-tech enterprise. The company was launched on the Shanghai Stock Exchange in February 2015. Listed (603222.SH). The company is located in the Zhejiang Huangyan High-tech Development Park, covering an area of nearly 400 acres and has a total number of employees reaching more than 2,000. Since its listing, the company has actively deployed its "big health strategy". It covers three major sectors: medical and health services, medical devices and chemical and pharmaceuticals, and has initially built a strategic pattern of "one main and two wings" dominated by medical devices and coordinated development of medical services and chemical and pharmaceuticals. Medical devices are the core business segment of Jimin Health. The products include safe injection puncture device series, pre-charge catheter flusher series, in vitro diagnostic series and hemodialysis concentrate series. Among them, safe injection puncture device series products are internationally , and both are in the leading position in China. The company has been engaged in the injection and puncture device business for more than 30 years and is a leading enterprise in the domestic safety syringe segment. Its main products include safety syringes, safety injection needles, sterile syringes, infusion devices and other products. The company's new product, pre-filled catheter irrigator, is a clinical application product combining medicine and equipment. This product is mainly used in the maintenance of vascular access devices such as PICC (central venous catheterization through peripheral venous ventricular puncture), venous indwelling needles. Its operation is simple and has a wide range of applications, can reduce the consumption of multiple materials, reduce hospital infection risks, reduce needle stab injuries, avoid medication errors, improve safety, improve work flow and efficiency, etc., and has gradually become a traditional saline and heparin dilution solution. Excellent alternative to flushing tube liquid. The company's hemodialysis concentrate series products adopt ultrapure water production process that far exceeds the technical indicators of dialysis water, C+A cleanliness production environment, and automated production equipment to effectively ensure product quality. The company's wholly-owned subsidiary, Spain LINEAR, has seven major product lines including a variety of diagnostic reagents, laboratory instruments and in vitro diagnostic medical products. Its core products, FOB fecal occult blood automatic immune monitoring and Helicobacter pylori detection kit, have a strong market. Competitiveness. There are 2 comprehensive hospitals in the medical and health service sector (Boao International Hospital and Ezhou Second Hospital), and they have cooperated with many hospitals in hemodialysis business. In the future, the company will continue to plan comprehensive and specialized (oncology, kidney disease, etc.) hospitals, and is committed to building the company into a big health industry group. There are nearly 40 infusion varieties in the chemical pharmaceutical sector, and they have various products such as balance, nutrition, therapeutic infusion and external irrigation agents. Currently, the company has three major production bases in Zhejiang, Shanghai and Spain, and has 6 wholly-owned or controlled subsidiaries: Hainan Jimin Boao International Hospital Co., Ltd., Ezhou Second Hospital Co., Ltd., Renia Chemical Co., Ltd., Jumin Biology Technology Co., Ltd., Zhejiang Jimintang Pharmaceutical Trading Co., Ltd., Taizhou Jurui Plastic Technology Co., Ltd.
Jimin Healthcare Management Co., Ltd.
Jimin Health Management Co., Ltd. (hereinafter referred to as the "Company") is a modern pharmaceutical enterprise founded in 1996. It is a key backbone enterprise in the pharmaceutical industry in Zhejiang Province and a national high-tech enterprise. The company was launched on the Shanghai Stock Exchange in February 2015. Listed (603222.SH). The company is located in the Zhejiang Huangyan High-tech Development Park, covering an area of nearly 400 acres and has a total number of employees reaching more than 2,000. Since its listing, the company has actively deployed its "big health strategy". It covers three major sectors: medical and health services, medical devices and chemical and pharmaceuticals, and has initially built a strategic pattern of "one main and two wings" dominated by medical devices and coordinated development of medical services and chemical and pharmaceuticals. Medical devices are the core business segment of Jimin Health. The products include safe injection puncture device series, pre-charge catheter flusher series, in vitro diagnostic series and hemodialysis concentrate series. Among them, safe injection puncture device series products are internationally , and both are in the leading position in China. The company has been engaged in the injection and puncture device business for more than 30 years and is a leading enterprise in the domestic safety syringe segment. Its main products include safety syringes, safety injection needles, sterile syringes, infusion devices and other products. The company's new product, pre-filled catheter irrigator, is a clinical application product combining medicine and equipment. This product is mainly used in the maintenance of vascular access devices such as PICC (central venous catheterization through peripheral venous ventricular puncture), venous indwelling needles. Its operation is simple and has a wide range of applications, can reduce the consumption of multiple materials, reduce hospital infection risks, reduce needle stab injuries, avoid medication errors, improve safety, improve work flow and efficiency, etc., and has gradually become a traditional saline and heparin dilution solution. Excellent alternative to flushing tube liquid. The company's hemodialysis concentrate series products adopt ultrapure water production process that far exceeds the technical indicators of dialysis water, C+A cleanliness production environment, and automated production equipment to effectively ensure product quality. The company's wholly-owned subsidiary, Spain LINEAR, has seven major product lines including a variety of diagnostic reagents, laboratory instruments and in vitro diagnostic medical products. Its core products, FOB fecal occult blood automatic immune monitoring and Helicobacter pylori detection kit, have a strong market. Competitiveness. There are 2 comprehensive hospitals in the medical and health service sector (Boao International Hospital and Ezhou Second Hospital), and they have cooperated with many hospitals in hemodialysis business. In the future, the company will continue to plan comprehensive and specialized (oncology, kidney disease, etc.) hospitals, and is committed to building the company into a big health industry group. There are nearly 40 infusion varieties in the chemical pharmaceutical sector, and they have various products such as balance, nutrition, therapeutic infusion and external irrigation agents. Currently, the company has three major production bases in Zhejiang, Shanghai and Spain, and has 6 wholly-owned or controlled subsidiaries: Hainan Jimin Boao International Hospital Co., Ltd., Ezhou Second Hospital Co., Ltd., Renia Chemical Co., Ltd., Jumin Biology Technology Co., Ltd., Zhejiang Jimintang Pharmaceutical Trading Co., Ltd., Taizhou Jurui Plastic Technology Co., Ltd.
Jilin DUBANG Pharmaceutical Co., Ltd.
The corporate style reflects the unified actions and style of the enterprise. Dubang Pharmaceutical's corporate style requires all members to fulfill their corporate responsibilities and maintain a consistent attitude of responsibility from individuals to collectives. That is, the personal fault should not be considered as a minor fault. From the perspective of personal responsibility, the impact on the company should be reflected in Dubang's spirit of full director and achieve a unified step in behavior and thinking. Dubang Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise integrating science, industry and trade and mainly focusing on the production of large-capacity injections. Dubang Pharmaceutical has always adhered to the historical mission of "benefiting people's livelihood, strengthening the country and safeguarding the country", and has taken "professional and responsible management and honest management" as its core concept. Not only has advanced modern production lines at home and abroad and various advanced testing instruments, but also has a high-quality management team. With advanced strategic awareness, standardized and strict quality assurance system, refined scientific management, and unique and excellent corporate culture , as well as the rapid response and decision-making ability to the market, the scale of the enterprise continues to grow, the core competitiveness and social popularity of the enterprise continues to increase, and all economic and technical indicators are among the forefront of the same industry in the country. Dubang Pharmaceutical now has two major pharmaceutical production bases in Dehui City, Jilin Province and Quzhou City, Zhejiang Province respectively. The company mainly produces large-capacity injections, ointments, creams and Class I pharmaceutical packaging materials required for large-capacity injections. "Walking far must be far away, and pursuit is endless." Dubang Pharmaceutical will continue to strive to promote the development of China's health industry, take scientific development and innovative development as the guiding ideology, vigorously promote the pace of scientific research and development and innovative development, continue to promote production technology and quality management, and steadily promote enterprise management and cultural construction. Dubang Pharmaceutical will move towards scale, group and internationalization with outstanding courage and a new and high-spirited attitude.
Jilin DUBANG Pharmaceutical Co., Ltd.
The corporate style reflects the unified actions and style of the enterprise. Dubang Pharmaceutical's corporate style requires all members to fulfill their corporate responsibilities and maintain a consistent attitude of responsibility from individuals to collectives. That is, the personal fault should not be considered as a minor fault. From the perspective of personal responsibility, the impact on the company should be reflected in Dubang's spirit of full director and achieve a unified step in behavior and thinking. Dubang Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise integrating science, industry and trade and mainly focusing on the production of large-capacity injections. Dubang Pharmaceutical has always adhered to the historical mission of "benefiting people's livelihood, strengthening the country and safeguarding the country", and has taken "professional and responsible management and honest management" as its core concept. Not only has advanced modern production lines at home and abroad and various advanced testing instruments, but also has a high-quality management team. With advanced strategic awareness, standardized and strict quality assurance system, refined scientific management, and unique and excellent corporate culture , as well as the rapid response and decision-making ability to the market, the scale of the enterprise continues to grow, the core competitiveness and social popularity of the enterprise continues to increase, and all economic and technical indicators are among the forefront of the same industry in the country. Dubang Pharmaceutical now has two major pharmaceutical production bases in Dehui City, Jilin Province and Quzhou City, Zhejiang Province respectively. The company mainly produces large-capacity injections, ointments, creams and Class I pharmaceutical packaging materials required for large-capacity injections. "Walking far must be far away, and pursuit is endless." Dubang Pharmaceutical will continue to strive to promote the development of China's health industry, take scientific development and innovative development as the guiding ideology, vigorously promote the pace of scientific research and development and innovative development, continue to promote production technology and quality management, and steadily promote enterprise management and cultural construction. Dubang Pharmaceutical will move towards scale, group and internationalization with outstanding courage and a new and high-spirited attitude.
Zhejiang Shapuaisi Pharmaceutical Co., Ltd.
Zhejiang Shapu Aisi Pharmaceutical Co., Ltd. was established in 1978. It is a comprehensive pharmaceutical enterprise specializing in drug research and development, production and operation. It was successfully listed on the A-share main board of the Shanghai Stock Exchange on July 2, 2014 ( Stock code: 603168). In October 2020, it successfully acquired Taizhou Obstetrics and Gynecology Hospital affiliated to Nantong University, officially entering the high-quality development of "pharmaceutical + medical care", and becoming a big health enterprise focusing on ophthalmology and obstetrics and gynecology. . The company has subsidiaries such as Zhejiang Shapu Aisi Pharmaceutical Sales Co., Ltd., Zhejiang Shapu Aisi Pharmacy Chain Co., Ltd., Taizhou Women and Children's Hospital Co., Ltd. Work hard to achieve strength, and strength creates excellence. Since its establishment, the company has passed the "High-tech Enterprise" certification for four consecutive times, and has been successively rated as "Key High-tech Enterprise of the National Torch Plan" and "Zhejiang Province Standard Innovation Enterprise". It has also been awarded "other sciences in China's chemical pharmaceutical industry" many times. Excellent product brand for drug use", "OTC excellent product brand for Chinese chemical pharmaceutical industry", "Social Responsibility Targeted Poverty Alleviation Award" and other honors. The company's main products, the anti-cataract, national second-class ophthalmic new drug "Shapuaisi" eye drops and the anti-glaucoma new drug "Daliang" eye drops were included in the "National Torch Plan Project". In addition, the company also has subdivided therapeutic areas such as antimicrobial drugs (cephalosporins), antimicrobial drugs (quinolones), water, electrolytes and acid-base balance drugs, including large-volume injections, oral solutions, tablets ( More than ten kinds of chemical preparations and traditional Chinese medicine preparation products, including cephalosporins), hard capsules (including cephalosporins), etc. Social responsibility, public welfare first. Shapu Aisi actively assumes social responsibility and devotes himself to public welfare undertakings. In recent years, the company has successively carried out a series of large-scale public welfare actions such as "Finishing China", "Concentric Circle·Government Consciousness", "Welcome a Century, and Performing Bailisha Pharmaceutical Charity to the Original Intention", and established the "Public Love Tongxin Charity Special Fund", etc. Give back to the society with practical actions, guide positive energy to spread, and continuously contribute to the development of China's public welfare undertakings.
Zhejiang Shapuaisi Pharmaceutical Co., Ltd.
Zhejiang Shapu Aisi Pharmaceutical Co., Ltd. was established in 1978. It is a comprehensive pharmaceutical enterprise specializing in drug research and development, production and operation. It was successfully listed on the A-share main board of the Shanghai Stock Exchange on July 2, 2014 ( Stock code: 603168). In October 2020, it successfully acquired Taizhou Obstetrics and Gynecology Hospital affiliated to Nantong University, officially entering the high-quality development of "pharmaceutical + medical care", and becoming a big health enterprise focusing on ophthalmology and obstetrics and gynecology. . The company has subsidiaries such as Zhejiang Shapu Aisi Pharmaceutical Sales Co., Ltd., Zhejiang Shapu Aisi Pharmacy Chain Co., Ltd., Taizhou Women and Children's Hospital Co., Ltd. Work hard to achieve strength, and strength creates excellence. Since its establishment, the company has passed the "High-tech Enterprise" certification for four consecutive times, and has been successively rated as "Key High-tech Enterprise of the National Torch Plan" and "Zhejiang Province Standard Innovation Enterprise". It has also been awarded "other sciences in China's chemical pharmaceutical industry" many times. Excellent product brand for drug use", "OTC excellent product brand for Chinese chemical pharmaceutical industry", "Social Responsibility Targeted Poverty Alleviation Award" and other honors. The company's main products, the anti-cataract, national second-class ophthalmic new drug "Shapuaisi" eye drops and the anti-glaucoma new drug "Daliang" eye drops were included in the "National Torch Plan Project". In addition, the company also has subdivided therapeutic areas such as antimicrobial drugs (cephalosporins), antimicrobial drugs (quinolones), water, electrolytes and acid-base balance drugs, including large-volume injections, oral solutions, tablets ( More than ten kinds of chemical preparations and traditional Chinese medicine preparation products, including cephalosporins), hard capsules (including cephalosporins), etc. Social responsibility, public welfare first. Shapu Aisi actively assumes social responsibility and devotes himself to public welfare undertakings. In recent years, the company has successively carried out a series of large-scale public welfare actions such as "Finishing China", "Concentric Circle·Government Consciousness", "Welcome a Century, and Performing Bailisha Pharmaceutical Charity to the Original Intention", and established the "Public Love Tongxin Charity Special Fund", etc. Give back to the society with practical actions, guide positive energy to spread, and continuously contribute to the development of China's public welfare undertakings.
Fresenius Kabi (China) Investment Co., Ltd.
Fresenius Cabi is a global enterprise focusing on the fields of infusion, blood transfusion and clinical nutrition. Fresenius Cabi provides reliable medical guarantees for patients with severe and chronic diseases with high-quality medicines, medical devices and services. Fresenius Cabi ’s product range includes intravenous medications, infusion therapy, clinical nutrition, and the medical devices required to apply these products. In the field of biosimilars, Fresenius Cabi focuses on autoimmune diseases and oncology. In terms of blood transfusion medicine and cell therapy devices, Fisseus Cabi provides blood component collection and in vitro cell therapy products. Taking care of life as its mission, Ferseniusca is committed to providing medical staff with essential medicines and technologies and helping them find quality solutions to solve problems. Since entering China, Fresenius Cabi has always regarded "caring for life" as the driving force for continuous development and progress, and is committed to helping the Chinese people improve their health and quality of life. Rooted in China for more than 30 years, Fresenius Cabi has been engaged in medicines, clinical nutrition, medical devices and other fields, thanks to its excellent products and technologies, standardized management, professional services, and efficient operation of R&D, production and marketing systems.业务领域取得骄人业绩，并发展成为中国临床营养、肾病营养治疗和麻醉治疗领域的领导者之一。
Fresenius Kabi (China) Investment Co., Ltd.
Fresenius Cabi is a global enterprise focusing on the fields of infusion, blood transfusion and clinical nutrition. Fresenius Cabi provides reliable medical guarantees for patients with severe and chronic diseases with high-quality medicines, medical devices and services. Fresenius Cabi ’s product range includes intravenous medications, infusion therapy, clinical nutrition, and the medical devices required to apply these products. In the field of biosimilars, Fresenius Cabi focuses on autoimmune diseases and oncology. In terms of blood transfusion medicine and cell therapy devices, Fisseus Cabi provides blood component collection and in vitro cell therapy products. Taking care of life as its mission, Ferseniusca is committed to providing medical staff with essential medicines and technologies and helping them find quality solutions to solve problems. Since entering China, Fresenius Cabi has always regarded "caring for life" as the driving force for continuous development and progress, and is committed to helping the Chinese people improve their health and quality of life. Rooted in China for more than 30 years, Fresenius Cabi has been engaged in medicines, clinical nutrition, medical devices and other fields, thanks to its excellent products and technologies, standardized management, professional services, and efficient operation of R&D, production and marketing systems.业务领域取得骄人业绩，并发展成为中国临床营养、肾病营养治疗和麻醉治疗领域的领导者之一。
Shijiazhuang Siyao Co., Ltd.
Shijiazhuang SiPharma Group (Shijiazhuang SiPharma Co., Ltd.) is a large high-tech pharmaceutical company that coordinates research and development and industrialization in multiple fields of industrial chains such as innovative drugs, generic drugs, specialty raw materials, high-end preparations and pharmaceutical packaging materials. It has entered China. The ranks of outstanding brand enterprises in the chemical pharmaceutical industry for exporting preparations. In 2007, the company was listed on the main board of Hong Kong (Shi Si Pharmaceutical Group 02005.HK). The group has been through wind and rain for more than seventy years, forging ahead. Especially in the past twenty years, under the leadership of Mr. Qu Jiguang, the leader of the group, he has transformed from a workshop-style small factory to a large listed company, and the company has achieved a complete transformation and a qualitative leap. At present, the group has 10 subsidiaries, more than 6,500 employees, assets exceeding 10 billion yuan, and main business income exceeding 6 billion yuan. It has the R&D, production, and export of innovative drugs, generic drugs, specialty raw materials, high-end preparations, biological agents and There are multiple business development patterns in industries such as pharmaceutical packaging materials. The group has formed a full industrial chain from special raw materials and new preparations to pharmaceutical packaging materials research and development, production and application. The annual production capacity of injections can reach 4 billion (pcs/bottles/bags), and the production scale and technical level are among the forefront of the same industry. Flexible operation methods and differentiated marketing and services have made the group's brand products win praise and praise from customers and consumers. The products radiate across the country and are exported to more than 90 countries and regions overseas.
Shijiazhuang Siyao Co., Ltd.
Shijiazhuang SiPharma Group (Shijiazhuang SiPharma Co., Ltd.) is a large high-tech pharmaceutical company that coordinates research and development and industrialization in multiple fields of industrial chains such as innovative drugs, generic drugs, specialty raw materials, high-end preparations and pharmaceutical packaging materials. It has entered China. The ranks of outstanding brand enterprises in the chemical pharmaceutical industry for exporting preparations. In 2007, the company was listed on the main board of Hong Kong (Shi Si Pharmaceutical Group 02005.HK). The group has been through wind and rain for more than seventy years, forging ahead. Especially in the past twenty years, under the leadership of Mr. Qu Jiguang, the leader of the group, he has transformed from a workshop-style small factory to a large listed company, and the company has achieved a complete transformation and a qualitative leap. At present, the group has 10 subsidiaries, more than 6,500 employees, assets exceeding 10 billion yuan, and main business income exceeding 6 billion yuan. It has the R&D, production, and export of innovative drugs, generic drugs, specialty raw materials, high-end preparations, biological agents and There are multiple business development patterns in industries such as pharmaceutical packaging materials. The group has formed a full industrial chain from special raw materials and new preparations to pharmaceutical packaging materials research and development, production and application. The annual production capacity of injections can reach 4 billion (pcs/bottles/bags), and the production scale and technical level are among the forefront of the same industry. Flexible operation methods and differentiated marketing and services have made the group's brand products win praise and praise from customers and consumers. The products radiate across the country and are exported to more than 90 countries and regions overseas.
Baxter (China) Investment Co., Ltd.
Baxter makes changes to the lives of millions of people around the world every day. The company's products and therapies are found in hospitals and clinics—from emergency rooms to operating rooms, from pharmacies to intensive care units—and improve patients' home treatment. For more than 80 years, I have always been at the important intersection of saving and continuing my life. Now, Baxter has the determination and ability to seize opportunities in the next few years to bring about change to global healthcare. Baxter came to China in the 1980s and is one of the largest multinational medical companies to enter the Chinese medical market earlier. Adhering to the corporate mission of "saving and continuing life", Baxter focuses on assisting in improving medical standards, expanding medical accessibility, and giving back to society, making meaningful contributions to the lives and quality of life of Chinese patients and helping China Sustainable development of medical care. Currently, Baxter has established 11 institutions and offices, 5 factories, 1 R&D center, and 1 technical service center in China.
Baxter (China) Investment Co., Ltd.
Baxter makes changes to the lives of millions of people around the world every day. The company's products and therapies are found in hospitals and clinics—from emergency rooms to operating rooms, from pharmacies to intensive care units—and improve patients' home treatment. For more than 80 years, I have always been at the important intersection of saving and continuing my life. Now, Baxter has the determination and ability to seize opportunities in the next few years to bring about change to global healthcare. Baxter came to China in the 1980s and is one of the largest multinational medical companies to enter the Chinese medical market earlier. Adhering to the corporate mission of "saving and continuing life", Baxter focuses on assisting in improving medical standards, expanding medical accessibility, and giving back to society, making meaningful contributions to the lives and quality of life of Chinese patients and helping China Sustainable development of medical care. Currently, Baxter has established 11 institutions and offices, 5 factories, 1 R&D center, and 1 technical service center in China.
Huaren Pharmaceutical Co., Ltd.
Huaren Pharmaceutical was founded in May 1998. It is a modern pharmaceutical and health industry group integrating R&D, production and sales, mainly focusing on preparations, raw materials, pharmaceutical packaging materials and medical devices. In August 2010, the company was successfully listed on the Shenzhen Stock Exchange, with the stock abbreviation "Huaren Pharmaceutical" and the stock code "300110". In July 2019, the company made an equity change, and the Xi'an Qujiang New District Management Committee became the actual controller of the company. After more than 20 years of development, the company's business focuses on the fields of nephrology, respiratory medicine, anaesthesia and large-capacity preparations, and has successively built five major production bases in Qingdao, Rizhao, Xiaogan, Pubei and Hefei, with a total production capacity of 950 million bags. (bottle), all production lines have passed the new version of GMP certification. The company's main products include small-volume injections, peritoneal dialysate, therapeutic infusions, basic infusions, medical devices, tablets, capsules, powders, granules, supporting drug packaging, big health products and raw materials, etc., and currently available Pentazocin injection, doxotheline injection, glycerol fructose sodium chloride injection, low-calcium peritoneal dialysate, etc., has achieved the "raw materials + preparations + pharmaceutical packaging materials" Integrated development. Taking innovation as the soul of development, in recent years, the company has actively grasped strategic development opportunities, focused on the treatment direction of nephrology, respiratory medicine, and semen anesthetics, screened new varieties such as large-capacity preparations, benchmarked against domestic and foreign first-line enterprises, and continued to increase R&D Invest, enrich R&D pipelines, enrich product lines, and enhance sustainable development capabilities. In the future, the company will actively respond to the national "Healthy China" strategy, support the construction of product strength, and actively promote the strategic layout of medical and health through independent research and development and collaborative innovation, and strive to grow into a combination of raw materials, preparations, medical devices, A pharmaceutical and health industry group that develops in a coordinated manner in pharmaceutical packaging materials and other sectors.
Huaren Pharmaceutical Co., Ltd.
Huaren Pharmaceutical was founded in May 1998. It is a modern pharmaceutical and health industry group integrating R&D, production and sales, mainly focusing on preparations, raw materials, pharmaceutical packaging materials and medical devices. In August 2010, the company was successfully listed on the Shenzhen Stock Exchange, with the stock abbreviation "Huaren Pharmaceutical" and the stock code "300110". In July 2019, the company made an equity change, and the Xi'an Qujiang New District Management Committee became the actual controller of the company. After more than 20 years of development, the company's business focuses on the fields of nephrology, respiratory medicine, anaesthesia and large-capacity preparations, and has successively built five major production bases in Qingdao, Rizhao, Xiaogan, Pubei and Hefei, with a total production capacity of 950 million bags. (bottle), all production lines have passed the new version of GMP certification. The company's main products include small-volume injections, peritoneal dialysate, therapeutic infusions, basic infusions, medical devices, tablets, capsules, powders, granules, supporting drug packaging, big health products and raw materials, etc., and currently available Pentazocin injection, doxotheline injection, glycerol fructose sodium chloride injection, low-calcium peritoneal dialysate, etc., has achieved the "raw materials + preparations + pharmaceutical packaging materials" Integrated development. Taking innovation as the soul of development, in recent years, the company has actively grasped strategic development opportunities, focused on the treatment direction of nephrology, respiratory medicine, and semen anesthetics, screened new varieties such as large-capacity preparations, benchmarked against domestic and foreign first-line enterprises, and continued to increase R&D Invest, enrich R&D pipelines, enrich product lines, and enhance sustainable development capabilities. In the future, the company will actively respond to the national "Healthy China" strategy, support the construction of product strength, and actively promote the strategic layout of medical and health through independent research and development and collaborative innovation, and strive to grow into a combination of raw materials, preparations, medical devices, A pharmaceutical and health industry group that develops in a coordinated manner in pharmaceutical packaging materials and other sectors.
Shandong Qidu Pharmaceutical Co., Ltd.
Shandong Qidu Pharmaceutical Co., Ltd. is located in Linzi District, Zibo City, the former capital of Qi State, a national historical and cultural city. It currently has more than 3,800 employees, covering an area of more than 600 mu, and a total assets of 3 billion yuan. Qidu Pharmaceutical is a comprehensive research-oriented pharmaceutical manufacturer mainly injectables and both oral preparations and raw materials. Its products mainly involve basic infusion, intravenous nutrition, plasma substitutes, anti-infection, anti-tumor, cardiovascular and cerebrovascular, In the fields of endocrine, pharmaceutical packaging materials and medical consumables, there are more than 190 drug production approval numbers. In the injection business segment, Qidu Pharmaceutical focuses on intravenous infusion and intravenous drug configuration technology research, has a professional sales team and technical support department, and can provide all kinds of medical institutions with full variety and specifications of intravenous drug combination plans and intravenous drug configurations. Technical support can provide high-quality products and services to all patients in need of emergency treatment through close cooperation with medical institutions. Since the establishment of the enterprise, especially since its restructuring in 1998, Qidu Pharmaceutical has adhered to the principle of "people-oriented, technology-oriented enterprise development", adhered to the business philosophy of "integrity, cooperation, and development", carried forward the corporate spirit of "pragmatic, innovative, and transcendent", and used brand Construction is the center, with scientific and technological innovation as the driving force, actively promote product research and development, strive to expand production scale, vigorously grasp marketing, strengthen quality control and standardized management, and achieve good and rapid development of all work. In the future, the company's work in all aspects will focus on the overall deployment of the group's development strategy planning, adhere to deepening reform and innovation-driven, adhere to strict management and internal development, adhere to people-oriented and technological development, and accelerate the growth of scale and incremental to quality and efficiency. We will continue to move towards the grand vision and goal of "a century-old capital and international capital", and strive to make new and greater contributions to local economic and social development and the development of the motherland's medical industry.
Shandong Qidu Pharmaceutical Co., Ltd.
Shandong Qidu Pharmaceutical Co., Ltd. is located in Linzi District, Zibo City, the former capital of Qi State, a national historical and cultural city. It currently has more than 3,800 employees, covering an area of more than 600 mu, and a total assets of 3 billion yuan. Qidu Pharmaceutical is a comprehensive research-oriented pharmaceutical manufacturer mainly injectables and both oral preparations and raw materials. Its products mainly involve basic infusion, intravenous nutrition, plasma substitutes, anti-infection, anti-tumor, cardiovascular and cerebrovascular, In the fields of endocrine, pharmaceutical packaging materials and medical consumables, there are more than 190 drug production approval numbers. In the injection business segment, Qidu Pharmaceutical focuses on intravenous infusion and intravenous drug configuration technology research, has a professional sales team and technical support department, and can provide all kinds of medical institutions with full variety and specifications of intravenous drug combination plans and intravenous drug configurations. Technical support can provide high-quality products and services to all patients in need of emergency treatment through close cooperation with medical institutions. Since the establishment of the enterprise, especially since its restructuring in 1998, Qidu Pharmaceutical has adhered to the principle of "people-oriented, technology-oriented enterprise development", adhered to the business philosophy of "integrity, cooperation, and development", carried forward the corporate spirit of "pragmatic, innovative, and transcendent", and used brand Construction is the center, with scientific and technological innovation as the driving force, actively promote product research and development, strive to expand production scale, vigorously grasp marketing, strengthen quality control and standardized management, and achieve good and rapid development of all work. In the future, the company's work in all aspects will focus on the overall deployment of the group's development strategy planning, adhere to deepening reform and innovation-driven, adhere to strict management and internal development, adhere to people-oriented and technological development, and accelerate the growth of scale and incremental to quality and efficiency. We will continue to move towards the grand vision and goal of "a century-old capital and international capital", and strive to make new and greater contributions to local economic and social development and the development of the motherland's medical industry.
B. Braun offers a comprehensive range of surgical instruments, including bone-cutting tools, known for their precision and durability.
B. Braun Melsungen AG
B. Braun offers a comprehensive range of surgical instruments, including bone-cutting tools, known for their precision and durability.
Smith Medical Devices (Beijing) Co., Ltd.
ICU Medical was founded in 1984 and is headquartered in San Clemente, California. In 1992, the company issued its initial public offering of shares on Nasdaq (NASDAQ:ICUI). ICU Medical's main customers include: hospital emergency departments, wholesalers, mobile clinics, outpatient clinics, home health care and long-term care supply institutions, etc. Since its establishment, ICU company has maintained organic growth and extended its business to more than 90 countries and regions around the world through acquisitions. After more than 30 years of development, ICU Medical has now become one of the world's advanced infusion therapy companies (pure-play infusion therapy companies), with business covering more than 90 countries and regions around the world. The company's products include infusion solutions, smart infusion pumps, dedicated and non-special infusion kits and needle-free connectors, as well as pain management and safety software technologies designed to help achieve clinical, safety and workflow goals. In addition, ICU also manufactured the world's first needle-free automated infusion dispensing system with its advanced workflow technology, closed system transmission equipment (for equipped with hazardous infusion drugs) and cardiac monitoring system. The current business composition ratio of ICU is about: infusion consumables account for 40%; infusion systems account for 30%, infusion solutions account for 25%, and intensive care accounts for 5%. Among them, infusion consumables mainly include: gravity equipment, needleless intravenous injection connectors, as well as closed system transmission equipment and special infusion consumables. The infusion system includes: large-capacity and outpatient intravenous injection pumps, special infusion sets, electronic medical record interactive security software and on-site services. Infusion solutions include: disinfection solutions, infusion irrigation solutions and some nutritional solutions. Intensive care includes: hemodynamic monitoring systems for evaluating patient blood flow status, advanced sensors and catheters, and pressure sensors. ICU Medical's medical consumables always account for a high proportion of its product portfolio, ensuring that the company has always had good financial indicators. ICU Medical has direct branches in North America (USA, Canada), South America (Argentina, Chile, Peru, Colombia), Europe, the United Kingdom, South Africa, Australia and other regions, including China, India, Russia, Central Asia, Dealer channels are set up in Nordic countries and regions. In terms of production, ICU Medical has 4 factories, including 3 in the United States and 1 in Costa Rica. Among them, ICU Medical's investment in the Costa Ri processing plant reached US$13.2 million. In addition to producing more than 800 venous devices, the plant also produces award-winning Plum 360 and LifeCare PCA infusion pumps.
Smith Medical Devices (Beijing) Co., Ltd.
ICU Medical was founded in 1984 and is headquartered in San Clemente, California. In 1992, the company issued its initial public offering of shares on Nasdaq (NASDAQ:ICUI). ICU Medical's main customers include: hospital emergency departments, wholesalers, mobile clinics, outpatient clinics, home health care and long-term care supply institutions, etc. Since its establishment, ICU company has maintained organic growth and extended its business to more than 90 countries and regions around the world through acquisitions. After more than 30 years of development, ICU Medical has now become one of the world's advanced infusion therapy companies (pure-play infusion therapy companies), with business covering more than 90 countries and regions around the world. The company's products include infusion solutions, smart infusion pumps, dedicated and non-special infusion kits and needle-free connectors, as well as pain management and safety software technologies designed to help achieve clinical, safety and workflow goals. In addition, ICU also manufactured the world's first needle-free automated infusion dispensing system with its advanced workflow technology, closed system transmission equipment (for equipped with hazardous infusion drugs) and cardiac monitoring system. The current business composition ratio of ICU is about: infusion consumables account for 40%; infusion systems account for 30%, infusion solutions account for 25%, and intensive care accounts for 5%. Among them, infusion consumables mainly include: gravity equipment, needleless intravenous injection connectors, as well as closed system transmission equipment and special infusion consumables. The infusion system includes: large-capacity and outpatient intravenous injection pumps, special infusion sets, electronic medical record interactive security software and on-site services. Infusion solutions include: disinfection solutions, infusion irrigation solutions and some nutritional solutions. Intensive care includes: hemodynamic monitoring systems for evaluating patient blood flow status, advanced sensors and catheters, and pressure sensors. ICU Medical's medical consumables always account for a high proportion of its product portfolio, ensuring that the company has always had good financial indicators. ICU Medical has direct branches in North America (USA, Canada), South America (Argentina, Chile, Peru, Colombia), Europe, the United Kingdom, South Africa, Australia and other regions, including China, India, Russia, Central Asia, Dealer channels are set up in Nordic countries and regions. In terms of production, ICU Medical has 4 factories, including 3 in the United States and 1 in Costa Rica. Among them, ICU Medical's investment in the Costa Ri processing plant reached US$13.2 million. In addition to producing more than 800 venous devices, the plant also produces award-winning Plum 360 and LifeCare PCA infusion pumps.
A multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods.
Johnson & Johnson
A multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods.
Sandoz, a division of Novartis, is a global leader in generic pharmaceuticals, including saline solutions for medical use.
Novartis AG
Sandoz, a division of Novartis, is a global leader in generic pharmaceuticals, including saline solutions for medical use.
Sanofi (China) Investment Co., Ltd.
Sanofi is a world-leading pharmaceutical and health enterprise that focuses on patient needs and research, develop and promote innovative treatment solutions. Sanofi's main business covers three areas: pharmaceuticals, human vaccines and animal health care. In 1982, Sanofi opened an office in China, becoming one of the first multinational pharmaceutical companies to enter China. Sanofi is headquartered in Shanghai in China and has 11 regional offices in Beijing, Tianjin, Shenyang, Jinan, Shanghai, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou and Urumqi. Since entering China in 1982, Sanofi has brought more than 40 innovative drugs and vaccines to China, including key areas such as cardiovascular disease, central nervous system diseases, internal medicine diseases, diabetes, tumors and blood diseases.
Sanofi (China) Investment Co., Ltd.
Sanofi is a world-leading pharmaceutical and health enterprise that focuses on patient needs and research, develop and promote innovative treatment solutions. Sanofi's main business covers three areas: pharmaceuticals, human vaccines and animal health care. In 1982, Sanofi opened an office in China, becoming one of the first multinational pharmaceutical companies to enter China. Sanofi is headquartered in Shanghai in China and has 11 regional offices in Beijing, Tianjin, Shenyang, Jinan, Shanghai, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou and Urumqi. Since entering China in 1982, Sanofi has brought more than 40 innovative drugs and vaccines to China, including key areas such as cardiovascular disease, central nervous system diseases, internal medicine diseases, diabetes, tumors and blood diseases.
Pfizer Investment Co., Ltd.
Founded in 1849 and headquartered in New York, USA, Pfizer Inc. is a science-based, innovative, patient-first biopharmaceutical company. For more than 170 years, Pfizer has used scientific and global resources to provide treatment options for people to prolong their lives and significantly improve their quality of life. The global portfolio includes innovative medicines and vaccines. Every day, Pfizer employees all over the world are actively committed to promoting human health, promoting the prevention, treatment and curing of diseases, and actively responding to the current disease challenges and the chronic diseases of the times. In addition, Pfizer is working with health care providers, governments and communities to support and promote access to more reliable and affordable health care services for people around the world. This is consistent with Pfizer’s responsibility as a globally outstanding innovative biopharmaceutical company. In 1989, Pfizer entered the Chinese market. Currently, Pfizer's business in China covers more than 300 cities, with a total investment of more than US$1.5 billion, and has established an advanced production facility, 2 R&D centers (located in Shanghai Zhangjiang High-Tech Park and Wuhan Optical Valley respectively), Nearly 7,000 employees are distributed in business, R&D and production fields. Pfizer has launched high-quality innovative products in five major fields in China, including prescription drugs and vaccines in the fields of tumors, vaccines, anti-infection, inflammation and immunity, rare diseases, etc. The strong and complete product line is designed to meet the health needs of all stages of life.
Pfizer Investment Co., Ltd.
Founded in 1849 and headquartered in New York, USA, Pfizer Inc. is a science-based, innovative, patient-first biopharmaceutical company. For more than 170 years, Pfizer has used scientific and global resources to provide treatment options for people to prolong their lives and significantly improve their quality of life. The global portfolio includes innovative medicines and vaccines. Every day, Pfizer employees all over the world are actively committed to promoting human health, promoting the prevention, treatment and curing of diseases, and actively responding to the current disease challenges and the chronic diseases of the times. In addition, Pfizer is working with health care providers, governments and communities to support and promote access to more reliable and affordable health care services for people around the world. This is consistent with Pfizer’s responsibility as a globally outstanding innovative biopharmaceutical company. In 1989, Pfizer entered the Chinese market. Currently, Pfizer's business in China covers more than 300 cities, with a total investment of more than US$1.5 billion, and has established an advanced production facility, 2 R&D centers (located in Shanghai Zhangjiang High-Tech Park and Wuhan Optical Valley respectively), Nearly 7,000 employees are distributed in business, R&D and production fields. Pfizer has launched high-quality innovative products in five major fields in China, including prescription drugs and vaccines in the fields of tumors, vaccines, anti-infection, inflammation and immunity, rare diseases, etc. The strong and complete product line is designed to meet the health needs of all stages of life.
Terumo (China) Investment Co., Ltd.
Import channels were interrupted during World War I, and Japanese medical scientists made efforts to localize the thermometers as their goal. In 1921, medical scientists led by Dr. Shibasaburo Kitari founded the Telmao Company. Since its establishment, Termau has inherited the innovative challenge spirit of Dr. Beili, implemented the company philosophy of "contributing to society through medical care", and is committed to delivering excellent innovative technologies to the medical site. Telmao Co., Ltd. was founded in 1921. Its products include disposable medical devices, blood transfusion tools series, pharmaceutical and nutritional medicine series, angiography and therapeutic catheter, medical electronic products series, artificial heart and lung product series, etc. Termau's products have been widely used in many countries and regions around the world. Termau's unique technology will make the medical process humanized and gentle. The application of Telmao's new technology can relieve pain and discomfort during medical treatment as much as possible. Telmau has always been committed to developing medical products that meet high standards, not only meeting high standards in terms of safety and precision, but also in maintaining patients' good recovery and quality of life. At present, Telmao has established two factories in Hangzhou and Changchun, China respectively. Termau will dedicate mild, easy-to-use healthcare products and technologies to the world in the 21st century. In order to strengthen the integrated management of R&D, production and sales in China, Telmao applied for the establishment of Telmao (China) Investment Co., Ltd. in August 2012, with a registered capital of US$30 million. According to the early business strategy, the sales ratio of domestic products will be gradually increased in the future. The establishment of Telmao (China) Investment Co., Ltd. has also taken a big step to integrating the Greater China Circle Management Model in the Mainland, Hong Kong, Macau and Taiwan markets.
Terumo (China) Investment Co., Ltd.
Import channels were interrupted during World War I, and Japanese medical scientists made efforts to localize the thermometers as their goal. In 1921, medical scientists led by Dr. Shibasaburo Kitari founded the Telmao Company. Since its establishment, Termau has inherited the innovative challenge spirit of Dr. Beili, implemented the company philosophy of "contributing to society through medical care", and is committed to delivering excellent innovative technologies to the medical site. Telmao Co., Ltd. was founded in 1921. Its products include disposable medical devices, blood transfusion tools series, pharmaceutical and nutritional medicine series, angiography and therapeutic catheter, medical electronic products series, artificial heart and lung product series, etc. Termau's products have been widely used in many countries and regions around the world. Termau's unique technology will make the medical process humanized and gentle. The application of Telmao's new technology can relieve pain and discomfort during medical treatment as much as possible. Telmau has always been committed to developing medical products that meet high standards, not only meeting high standards in terms of safety and precision, but also in maintaining patients' good recovery and quality of life. At present, Telmao has established two factories in Hangzhou and Changchun, China respectively. Termau will dedicate mild, easy-to-use healthcare products and technologies to the world in the 21st century. In order to strengthen the integrated management of R&D, production and sales in China, Telmao applied for the establishment of Telmao (China) Investment Co., Ltd. in August 2012, with a registered capital of US$30 million. According to the early business strategy, the sales ratio of domestic products will be gradually increased in the future. The establishment of Telmao (China) Investment Co., Ltd. has also taken a big step to integrating the Greater China Circle Management Model in the Mainland, Hong Kong, Macau and Taiwan markets.
GlaxoSmithKline (China) Investment Co., Ltd.
GSK is a global biopharmaceutical company with the mission of "growing science, technology and talents, working together to surpass and overcome diseases." Committed to positively impact the health of 2.5 billion people over the next decade. In China, GSK (GSK) is always committed to helping improve the health, life and future of the Chinese people. Vaccines: GSK is a leading vaccine supplier in the Chinese market, committed to improving the accessibility of vaccines to Chinese patients and consumers. Our children and adult vaccines can prevent a variety of diseases: shingles, cervical cancer vaccines, and hepatitis B virus vaccines, including two dosage forms of adults and children. Prescription Drugs: GSK's prescription drug business has a rich innovative and mature product portfolio. In China, it is currently focusing on the following diseases: respiratory system, hepatitis, neurological diseases, HIV/AIDS, as well as immune system diseases including systemic lupus erythematosus and pulmonary hypertension, eosinophilic granulomatous polyangiitis (EGPA) ) Rare diseases.
GlaxoSmithKline (China) Investment Co., Ltd.
GSK is a global biopharmaceutical company with the mission of "growing science, technology and talents, working together to surpass and overcome diseases." Committed to positively impact the health of 2.5 billion people over the next decade. In China, GSK (GSK) is always committed to helping improve the health, life and future of the Chinese people. Vaccines: GSK is a leading vaccine supplier in the Chinese market, committed to improving the accessibility of vaccines to Chinese patients and consumers. Our children and adult vaccines can prevent a variety of diseases: shingles, cervical cancer vaccines, and hepatitis B virus vaccines, including two dosage forms of adults and children. Prescription Drugs: GSK's prescription drug business has a rich innovative and mature product portfolio. In China, it is currently focusing on the following diseases: respiratory system, hepatitis, neurological diseases, HIV/AIDS, as well as immune system diseases including systemic lupus erythematosus and pulmonary hypertension, eosinophilic granulomatous polyangiitis (EGPA) ) Rare diseases.
